Ionis Pharmaceuticals, Inc. Common Stock (IONS) Financials

Key financial figures for Ionis Pharmaceuticals, Inc. Common Stock (Q3 2026).

Ionis Pharmaceuticals, Inc. reported revenue of $242.7 million for Q3 FY2026, up 54.9% from the same period a year earlier. The company posted a net loss of $110.0 million, or -$0.66 per share. Operating margin came to -53.85%, against -102.21% a year earlier. Free cash flow for the period was -$192.1 million. Across the last 5 reported quarters, quarterly revenue has risen from $156.7 million in Q3 FY2025 to $242.7 million in Q3 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Ionis Pharmaceuticals, Inc. are on the SentiSense financials page.

Revenue
$243M
Net Income
-$110M
EPS
$-0.66
Total Assets
$2.9B
Operating Cash Flow
-$179M

Recent quarters

PeriodRevenueNet IncomeEPSOperating MarginFree Cash Flow
Q3 FY2026$243M-$110M-$0.66-53.85%-$192M
Q2 FY2026$268M-$115M-$0.69-38.18%$549M
Q1 FY2026$246M-$93M-$0.56-47.72%-$815M
Q4 FY2025$203M-$229M-$1.41-105.91%-$159M
Q3 FY2025$157M-$129M-$0.80-102.21%-$135M

Recent fiscal years

PeriodRevenueNet IncomeEPSOperating MarginFree Cash Flow
FY2025$944M-$381M-$2.38-40.47%-$320M
FY2024$705M-$454M-$3.04-67.37%-$546M
FY2023$788M-$366M-$2.56-44.91%-$336M

Frequently asked questions

What was Ionis Pharmaceuticals, Inc.'s revenue last quarter?

Ionis Pharmaceuticals, Inc. reported revenue of $242.7 million for Q3 FY2026, up 54.9% from the same period a year earlier.

Is Ionis Pharmaceuticals, Inc. profitable?

Not in its most recent reported period. Ionis Pharmaceuticals, Inc. reported a net loss of $110.0 million for Q3 FY2026, a net margin of -45.31% on revenue.

How has Ionis Pharmaceuticals, Inc.'s margin trended?

Operating margin was -53.85% in Q3 FY2026, compared with -102.21% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.

How much free cash flow did Ionis Pharmaceuticals, Inc. generate?

Ionis Pharmaceuticals, Inc. generated free cash flow of -$192.1 million in Q3 FY2026, after capital expenditure.

Full income statement, balance sheet and cash flow for Ionis Pharmaceuticals, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.